Latest Japanese recommendations include first nod for Novo's insulin degludec

Novo Nordisk's Tresiba (insulin degludec) has received its first positive approval opinion worldwide, in Japan, following a regulatory filing in this market last December.

Novo Nordisk's Tresiba (insulin degludec) has received its first positive approval opinion worldwide, in Japan, following a regulatory filing in this market last December.

The long-acting, once-daily basal insulin analogue is indicated for both type 1 and 2 disease and will provide competition to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category